title: Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
abstract: Published data have shown inconsistent results about the pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. This meta-analysis aimed to summarize published findings and provide more reliable association. A total of 53 eligible studies including 7433 patients were included. Patients bearing the favorable TrpTrp and TrpArg genotypes of Arg194Trp were more likely to better response rates to platinum-based chemotherapy compared to those with the unfavorable ArgArg genotype (TrpTrp+TrpArg vs. ArgArg: odds ratio (OR) = 2.02, 95% CI, 1.66-2.45). The GlnGln and GlnArg genotypes of Arg399Gln were significantly associated with the poorer response rates compared to those with the ArgArg genotype (GlnGln +GlnArg vs. ArgArg: OR = 0.68, 95% CI, 0.54-0.86). The GlnGln genotype might be more closely associated with shorter survival time and higher risks of death for patients (GlnGln vs. ArgArg: hazard ratio (HR) = 1.14, 95% CI, 0.75-1.75). Our cumulative meta-analyses indicated a distinct apparent trend toward a better response rate for Arg194Trp, but a poorer response rate in Arg399Gln. These findings indicate a predictive role of XRCC1 polymorphisms in clinical outcomes. The use of XRCC1 polymorphisms as predictive factor of clinical outcomes in personalized chemotherapy treatment requires further verification from large well-designed pharmacogenetics studies.
authors.affiliation: College of Biological Science and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.|Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing 100193, People's Republic of China.
authors.forename: Zhengrong
authors.initials: Z
authors.lastname: Yuan
authors.affiliation: National Animal Husbandry Service, Beijing 100125, People's Republic of China.
authors.forename: Jiao
authors.initials: J
authors.lastname: Li
authors.affiliation: College of Biological Science and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors.forename: Ruiqi
authors.initials: R
authors.lastname: Hu
authors.affiliation: College of Biological Science and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Jiao
authors.affiliation: College of Biological Science and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Han
authors.affiliation: College of Biological Science and Technology, Beijing Forestry University, Beijing 100083, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Weng
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D016017:Odds Ratio; D010597:Pharmacogenetics; D010984:Platinum / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016896:Treatment Outcome; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D010984:Platinum